RT Journal Article
SR Electronic
T1 Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4637
OP 4644
DO 10.21873/anticanres.12768
VO 38
IS 8
A1 SHIMIZU, KATSUHIKO
A1 OKITA, RIKI
A1 SAISHO, SHINSUKE
A1 MAEDA, AI
A1 NOJIMA, YUJI
A1 NAKATA, MASAO
YR 2018
UL http://ar.iiarjournals.org/content/38/8/4637.abstract
AB Background/Aim: There is no clear evidence in the literature regarding the regulation of programmed cell death-ligand 1 (PD-L1) expression by cyclo-oxygenase-2 (COX2). In this study, whether PD-L1 expression was regulated by COX2 activity was examined in vitro. Materials and Methods: Resected lung cancer specimens were analyzed for PD-L1 and COX2 expression by immunohistochemical analysis. Next, co-localization of PD-L1 and COX2 expression was analyzed by double-fluorescence staining. Lastly, the effect of COX2 inhibition on the expression of PD-L1 was examined using lung cancer cell lines. Results: PD-L1 expression was significantly correlated with COX2 expression in the resected specimens. The majority of cancer cells that expressed PD-L1 also co-expressed COX2. However, treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression. Conclusion: Our results suggest that COX2 inhibition might have no effect on the usage of immune checkpoint inhibitors in lung cancer treatment.